Abstract-The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene might have consequences for the risks of vascular diseases. We examined the ACE genotype and the effects of a perindopril-based blood pressure-lowering regimen on macrovascular events, dementia, and cognitive decline among hypertensive and nonhypertensive patients with a history of cerebrovascular disease. ACE I/D genotypes were measured in 5688 of 6105 individuals with previous stroke or transient ischemic attack who participated in the PROGRESS trial. The DD genotype was significantly (PϽ0.0001) less frequent in Asian subjects (Chinese and Japanese, 14.7%) than in non-Asian subjects (32.0%). Controlling for racial background, there were no associations between ACE genotypes and cerebrovascular disease history or cardiovascular risk factors, including baseline blood pressure. The ACE genotype was not associated with the long-term risks of stroke, cardiac events, mortality, dementia, or cognitive decline; neither did the ACE genotype predict the blood pressure reduction associated with the use of the ACE inhibitor perindopril. Similarly, there was no evidence that the ACE genotype modified the relative benefits of ACE inhibitor-based therapy over placebo. This study provides no evidence that in patients with cerebrovascular disease, knowledge of ACE genotype is useful for predicting either the risk of disease or the benefits of perindopril-based blood pressure-lowering treatment. 
I
schemic and hemorrhagic stroke and their associated risk factors show familial aggregation, such that the relative risk of stroke is approximately doubled in the presence of stroke in a first-degree relative. 1 Genetic causes have been found for rare, specific cerebrovascular abnormalities. 1 More generally, a recent genome scan identified a susceptibility locus for stroke on chromosome 5q12, 2 and other studies have suggested candidate genes, including that encoding the angiotensin-converting enzyme (ACE).
Common variation in the ACE gene structure is defined by the insertion (I) or deletion (D) of 287 bp of nonsense DNA in intron 16, resulting in 3 genotypes (DD, ID, II). The ACE I/D polymorphism is presumed to be in linkage disequilibrium with functional variants that determine enzyme activity, 3 such that the D allele is associated with increased ACE activity in white 4 and Asian 5, 6 subjects. However, the I/D polymorphism does not appear to be associated with ACE activity in black subjects. 7 Although the polymorphism is not associated with differences in plasma angiotensin II or aldosterone even in white subjects, 8 changes in tissue ACE activity 9 might be relevant to blood vessels and stroke.
Most studies of the ACE gene, blood pressure, and stroke have been neither large nor prospective, and the findings have been either inconclusive or conflicting. The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a large-scale, randomized trial designed to determine the effects of an ACE inhibitor-based blood pressure-lowering regimen on the risks of major vascular events among individuals with a history of stroke or transient ischemic attack (TIA). 10 There were substantial benefits of this regimen for the risk of stroke, 10 and we report here the associations between the ACE gene I/D polymorphisms and blood pressure, the risk of vascular events, and the effects of study treatment on vascular events.
Methods

Study Design
The design of the PROGRESS study has been described in detail elsewhere. 10 In brief, 6105 participants were recruited from 172 collaborating centers in 10 countries from Australasia, Europe, and Asia between 1995 and 1997. The institutional ethics committee of each collaborating center approved the trial and the genetic substudy, and all participants provided written, informed consent. Individuals were potentially eligible if they had a history of cerebrovascular disease (stroke or TIA, but not subarachnoid hemorrhage) within the previous 5 years and no clear indication for or contraindication to treatment with an ACE inhibitor. There were no blood pressure criteria for entry.
Potentially eligible individuals entered a 4-week, prerandomization run-in period, during which they received open-labeled perindopril (2 mg daily for 2 weeks, followed by 4 mg daily for another 2 weeks). Participants who tolerated and adhered to the run-in therapy with perindopril were randomly assigned, in a double-blind manner, to continued active treatment or matching placebo(s). Active treatment comprised a flexible treatment regimen based on perindopril (4 mg daily) in all participants, with the addition of indapamide (2.5 mg daily, or 2 mg daily in Japan) in those for whom the responsible study physician judged that there was no specific indication for nor contraindication to the use of a diuretic. Those participants assigned to placebo received 1 or 2 tablets identical in appearance to the active agent(s). All other aspects of medical care were left to the discretion of the responsible physician.
Data Collection and Follow-Up
Before randomization, information was collected about the history of vascular disease, vascular risk factors, and current medications. After randomization, participants were scheduled to be seen on 5 occasions in the first year and every 6 months thereafter until the end of the scheduled follow-up period or death. At each visit, blood pressure was measured in duplicate, to the nearest 2 mm Hg, by using a standard mercury sphygmomanometer.
Outcomes
In addition to blood pressure, outcomes for these analyses included major vascular events and cognitive decline, which were defined as follows: (1) fatal and nonfatal stroke, with separate classification of ischemic and hemorrhagic stroke subtypes; (2) major coronary heart disease, defined as nonfatal myocardial infarction or death due to coronary heart disease, 11 with separate analyses of nonfatal myocardial infarction; (3) major vascular events, defined as a composite of nonfatal stroke, nonfatal myocardial infarction, or death due to any vascular cause (including sudden unexplained death); (4) mortality from any cause; (5) dementia, diagnosed according to DSM-IV criteria; 12 and (6) cognitive decline, defined as a fall of at least 3 points in the Mini-Mental State Examination between baseline and final available assessment. 12 An independent end-point adjudication committee, blinded to study treatment allocation, reviewed source documentation for all suspected strokes, myocardial infarctions, and all deaths during follow-up; a separate dementia adjudication committee reviewed all dementia assessments. 12 
DNA Analyses
Samples of venous blood were collected in EDTA for extraction of DNA from buffy coats by using a salting-out procedure. Genotyping of the ACE I/D polymorphism was performed after polymerase chain reaction amplification of the region encompassing the polymorphism with 3 primers, ACE3U (TCTCGATCTCCTGACCTCGTGATCC), ACE2L (CCCTTAGCTCACCTCTGCTTGTAAG), and ACE1U (CTGGAGACCACTCCCATCCTTTCTC), by hybridization with allelespecific oligonucleotides. The sequence of allele-specific oligonucleotide and assay conditions are available at the Internet address http://www.genecanvas.org/polymorphism.asp-polϭACE_ID.htm.
Statistical Analysis
Baseline characteristics were compared between the 3 genotypes by 2 tests and logistic regression (for categorical variables) or ANOVA and general linear models (for continuous variables). HardyWeinberg equilibrium was tested by 2 tests. Differences between the 3 genotypes in the effects of active treatment on blood pressure were investigated by ANOVA (1) during the run-in phase of the trial, including all subsequently randomized patients with known genotype, comparing baseline with prerandomization blood pressure measurements; and (2) during the entire study period, including all randomized patients assigned to active treatment with known genotype, comparing baseline with final postrandomization blood pressure measurements. Average postrandomization differences in blood pressure between the randomized groups were also estimated by fitting linear mixed models, by using baseline and all available postrandomization blood pressure measurements with an interaction term to compare the effects in the 3 subgroups defined by genotype.
Longitudinal associations between ACE genotypes and events were investigated with the Cox proportional-hazards models for those outcomes for which a specific event date was available (all stroke and coronary outcomes) and logistic regression models for those outcomes for which a specific event date was not available (dementia and cognitive decline). Hazard ratios and odds ratios were calculated by using the II genotype as the reference group. All analyses were carried out first without adjustment and then with adjustment for potential confounding variables (treatment allocation, assignment to combination or single-drug therapy, Asian or nonAsian ethnicity).
The effects of randomized treatment on events for each individual genotype were also estimated by using Cox and logistic regression models. Because the overall effect of treatment on stroke was greater among participants treated with combination therapy than among those treated with single-drug therapy, 10 treatment effects were standardized for the proportions of the study population for whom combination (58%) or single-drug (42%) therapy was planned by taking weighted averages of the estimates obtained for the 2 therapies. Homogeneity of the effects of treatment among different genotypes was tested by adding interaction terms to the relevant statistical models. 13 
Results
Study Population and Baseline Characteristics
A total of 6105 individuals were randomized into PROGRESS. The current analyses include the 5688 randomized participants for whom ACE I/D genotyping was successful: of these, 2828 were in the active treatment group and 2860 were in the placebo group. These 5688 participants were representative of the total study participants in terms of their principal sociodemographic and clinical characteristics. 10 The 2132 Asian subjects (individuals recruited from the People's Republic of China or Japan) were younger (60.9 vs 65.7 years), had a lower body mass index (24.6 vs 26.4 kg/m 2 ), consumed less alcohol (18% vs 47%, Ն1 U per week) were more likely to have a history of stroke (92% vs 79%, and less likely to have a history of TIA or amaurosis fugax (12% vs 29%) than the 3556 non-Asian participants (all PϽ0.0001). The DD genotype was also significantly (PϽ0.0001) less frequent in Asian subjects (II 41.0%, ID 44.3%, DD 14.7%) than in non-Asian subjects (II 21.2%, ID 46.8%, DD 32.0%), but in both groups, genotypes were in Hardy-Weinberg equilibrium. Therefore, Table 1 provides baseline characteristics by genotype in Asian and non-Asian subjects separately. There were no significant differences in any of the baseline variables listed in Table 1 between the 3 genotypes. In particular, there were no differences in baseline systolic or diastolic blood pressure levels between the 3 genotype groups. This was true overall and separately for males and females and for participants who were and were not taking blood pressure-lowering medications at study entry (data not shown). The proportions assigned to each randomized treatment and the proportions managed with combination compared with single-drug therapy were well balanced between the 3 genotypes ( Table 1) .
Effects of ACE Genotype on Blood Pressure Reduction Achieved
During the 4-week run-in period, treatment with perindopril reduced the overall mean blood pressure from baseline to follow-up by 8.8/4.7 mm Hg (Table 2 ) among the randomized participants genotyped. The mean reduction in blood pressure during run-in did not differ between the 3 participant groups defined by each genotype (PՆ0.30 for systolic and diastolic blood pressure). This was true in both males and females separately, those participants already taking blood pressurelowering medication and those who were not, and in both Asian and non-Asian participants separately (data not shown). Similar analyses of the effects of perindoprilϮ indapamide on blood pressure during the mean 3.9-year postrandomization phase in the 2828 actively treated participants showed a mean 14.4/7.4 mm Hg reduction in blood pressure from baseline to final assessment (Table 2 ). Once again, there was no evidence that the effects of treatment varied between the participant groups defined on the basis of genotypes (PϾ0.57 for systolic and diastolic blood pressure). Finally, among all 5688 randomized participants with known genotype, the average difference in blood pressure between randomized groups during follow-up was 9.2/4.0 mm Hg. There was no evidence of significant variation (Pϭ0.19) in the corresponding estimates of the effects of treatment between groups defined by ACE genotype (II 9.1/4.1, ID 9.2/3.6, DD 9.2/4.6).
Associations of ACE Genotypes With the Risk of Vascular Events
Three-way analyses of the ACE genotypes identified no significant associations of ACE genotype with major outcomes in either unadjusted or adjusted analyses (Table 3) . Pairwise comparisons of ID and DD against the II reference group identified only small to moderate differences in the relative risks of events, with estimates of effect ranging between 0.70 (30% reduced risk) and 1.23 (23% increased risk) for the 9 outcomes. The only pairwise comparisons to provide statistically significant results were for the outcomes major vascular events and major coronary heart disease. In each case, the DD group had lower risks than the II group, although both were only borderline significant at the 5% level. There was no evidence that the associations of ACE genotype with the risks of vascular events were different between Asian and non-Asian participants (results not shown). No association between ACE genotype with the risks of vascular events were observed when the placebo group was considered alone (data not shown).
Associations of ACE Genotypes With the Effects of Active Treatment on the Risk of Vascular Events
The main study analyses showed overall beneficial effects of randomized treatment on the risks of all of the 8 outcomes studied here 10 -12 except for dementia, for which there was only a nonsignificant trend toward benefit. 12 There was no evidence that the beneficial effects of study treatment observed overall varied between the 3 participant groups defined by genotype. Although the confidence intervals about the estimates for individual genotypes were generally wide, all estimates for all outcomes were suggestive of benefit, except for a slight and nonsignificantly increased risk of death among participants with the ID genotype (Table 4) . However, neither for this nor for any other outcome was there any statistical evidence that the effects of treatment varied between ACE genotype subgroups (All P homogeneity Ն0.18).
Discussion
The PROGRESS study clearly demonstrated that among individuals with previous stroke or TIA, a perindopril-based blood pressure-lowering regimen reduced blood pressure and the risks of stroke, coronary heart disease, and cognitive decline. 10 -12 Although the activity of the ACE enzyme is to a significant extent determined by the ACE genotype in Asian 5, 6 and white 4, 8, 9 subjects, we could find no evidence of any association between the ACE I/D genotypes and the effects of the ACE inhibitor on study outcomes.
There is little evidence that ACE genotype is a major determinant of hypertension 14 or blood pressure variation, 8 and this was confirmed by the PROGRESS study. Despite the large size of the study and the precise estimates of blood pressure levels afforded, there were no identifiable associations of ACE genotype with baseline blood pressure levels. Similarly, although there has been debate as to whether ACE genotype might influence the reduction in blood pressure achieved with ACE inhibitor therapy, [15] [16] [17] [18] the PROGRESS study provides no evidence to support this hypothesis. In PROGRESS, the estimates of treatment effect obtained for each genotype were very precise and provided extremely good statistical power to detect, with 90% power, a difference in blood pressure reduction (last recorded minus baseline reading) of 3.5, 2.5, and 3.2 mm Hg. Moreover, the ACE genotype was not useful in predicting the significant falls in systolic and diastolic pressures during the 4-week run-in phase, during which all patients were exposed to perindopril, or among the 2828 of these patients assigned to active perindopril-based treatment during the approximate 4-year follow-up period. This was so, whether or not patients were receiving other (non-ACE inhibitor) antihypertensive therapy at the time. Nor was there any association between ACE genotypes and the mean postrandomization differences in blood pressure between participants assigned to active treatment and those assigned to placebo.
Although no association between ACE genotype and blood pressure could be identified, it remained possible that postulated blood pressure-independent effects of ACE inhibition might be associated with the ACE genotype. We were able to test for longitudinal associations between ACE genotypes and the incidence of predefined cerebrovascular outcomes. There was no evidence that the likelihood of a recurrent stroke (total, ischemic, or hemorrhagic) was any different for those with a particular ACE genotype. In PROGRESS, the estimates of treatment effect obtained for each genotype were precise; we had sufficient numbers to detect, with 90% power, relative risk reductions of 41%, 29%, and 35% (for DD, ID, and II, respectively) for stroke and of 35%, 23%, and 29% for major vascular disease. Although some studies suggested associations between the ACE D allele and increased carotid intima-medial thickness, 19 carotid plaque, 20 carotid stenosis, 21 and ischemic stroke, 22 the findings of PROGRESS confirm other negative association analyses. [23] [24] [25] [26] Patients with cerebrovascular disease, though at very high risk of stroke, also have substantially elevated risks of myocardial infarction and other cardiac events. 27 In the PROGRESS study, 150 incident cases of nonfatal myocardial infarction and a total of 255 major coronary events were observed in the genotyped subjects. Earlier reports of the association of ACE genotype with myocardial infarction were somewhat variable, 28 and in PROGRESS, there was no overall association between these events and ACE genotype. Pairwise comparisons did identify participants with the ACE DD genotype as being at slightly lesser risk of major coronary events and major vascular events compared with those with the ACE II genotype, although these differences were of borderline significance.
Prior studies had also suggested that the ACE gene might contribute to complications of cerebrovascular disease, such as vascular dementia, 29 and the ACE gene has been associated with both cognitive decline 30 and Alzheimer's disease. 31 In the PROGRESS study, careful assessment of cognitive function 12 identified several hundred patients who developed dementia and more with cognitive decline. However, there was no evidence that the likelihood of these events occurring during follow-up was associated with the ACE genotype. It has also been suggested that the ACE DD genotype might be associated with increased overall death rate. 32 However, in PROGRESS, rates of death during the 4-year follow-up were no more common in one ACE genotype group than any other. Finally, we could find no evidence that the demonstrated beneficial effects of perindopril-based therapy on cerebrovascular events, coronary events, and measures of cognitive function were influenced significantly by ACE genotype. The PROGRESS study selected individuals based on preexisting cerebrovascular disease, and there is therefore some uncertainty about the applicability of the findings of this study to the association between ACE genotype and risk among individuals without established disease. However, the findings concur with the prospective analyses of the 348 primary strokes observed over 12 years in the Physicians' Health Study, 26 suggesting that the absence of association may be consistent across both first and recurrent events and not a specific feature of this patient group.
Perspectives
These analyses of PROGRESS are among the most comprehensive assessment of the effects of ACE genotype on outcome to date. The ACE gene I/D polymorphisms do not appear to translate into significant phenotypic effects of ACE inhibitor treatment. These genotype analyses of PROGRESS provide no rationale for using ACE genotype to guide treatment decisions or to provide prognostic information relevant to cerebrovascular, cardiovascular, or cognitive function end points. 
